Domestic and foreign R&D spending by members of the Pharmaceutical Research and Manufacturers of America (PhRMA) declined 2.4% in 2011 to an estimated $49,476 million. Domestic spending fell 5.3%, but foreign R&D rose 9.2% to make up 78% and 22% of R&D spending, respectively. As a percentage of sales, total R&D was 16.7%. Sales by PhRMA member companies rose 1.5% in 2011 to $295,496 million, with foreign sales accounting for 38% of the total. As a percentage of total R&D personnel at PhRMA member companies, R&D staff totaled 93% and supported R&D non-staff represented 7% in 2010. Among 2010 R&D staff, 29%, 23%, 12%, and 12% worked in prehuman/preclinical, Phase 3, Phase 4 and Phase 2 research, respectively. In 2011, there were 3,240 compounds in development.

Source: PhRMA